Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (82)	12/7/1997 4:46:00 AM
From: Vector1	Respond to of 666

Peter, thanks for posting the letter from Bill Rastetter. Do you and others find it as odd as I do. Peter do you know when it was sent. Seems like IDEC is unhappy that CLTR is stealing the headlines during what Rastetter believes is their moment of glory. As for the abstact from the multicenter studies it appears that CLTR's data was very strong indeed. Based on the stock price someone was impressed with the CLTR presentation. All along the IDEC bears have been trying to cast Bexxar as a salvage/last resort type of treatment because of the so called additional side effects. Unfortunately they are confusing Bexxar with Y2B8 which does have some more severe side effect issues. The plain fact is that the side effects from Bexxar while more significant that Rixutan are not severe and certainly not as significant as CHOP. CLTR and IDEC are competitors and it will be interesting to see how it all shakes out. I think IDEC will do very well. Once approved Bexxar will take market share but there will be room for both products. V1